The NLMSF Patient-Caregiver Advocacy Network met on July 13 for a presentation on the CANCER CELL LINE PROJECT FOR LEIOMYOSARCOMA – a Patient-Driven Project for Global Research. Dr. Jesse Boehm from the Broad Institute of MIT/Harvard made a presentation which can be accessed here. The Rare Cancer Research Foundation (RCRF) is dedicated to curing rare cancers through strategic investments and innovative collaborations that facilitate effective research and accelerate the deployment of promising therapies. Pattern.org, part of the Rare Cancer Research Foundation, is a patient-research matching program that enables patients to directly donate their tumor tissue and medical data to research.
New therapies for LMS can’t be discovered until we systematically map the best drug targets. The Rare Cancer Dependency Map Initiative is creating patient models from living tissue and CRISPR/drug data to help researchers worldwide solve this challenge, together. If you have an upcoming LMS surgery scheduled, you can help this initiative by donating excess tissue from your procedure. Go to Pattern.org to learn more.
NLMSF is supporting the Rare Cancer Dependency Map Initiative at the Broad Institute which is described in the video below. This is a critical project for LMS research and we need your help! If you have an upcoming surgery for LMS, please consider donating tissue from your procedure. It’s free and all the arrangements will be handled by our friends at Pattern.org. Go to Pattern.org to learn more.
Here’s the link to our Rare Cancer Dependency Map video, provided to the NLMSF. We hope it will help engage patients and communicate about our project:
Progress from the initial Cancer Cell Line Project 2017 launch, with the NLMSF in collaboration with the Rare Cancer Research Foundation (RCRF) to accept LMS into the pilot project at that time. Since then, this is the progress and trajectory to date, as presented to the International LMS Research Roundtable. As planned, the Broad Institute of MIT/Harvard are working together with the Roundtable – within Workgroup #1 – CELL LINES /PDX Models.
The key to continuing progress is for patients to consent to donating tumor tissue to the Rare Cancer Research Foundation (Barbara VanHare): Pattern.org – prior to surgery (at least 2 weeks) for tumor tissue to be given to the Broad, to grow cell lines that can be cultivated and screened toward further Crispr Cas9 screening and repurposed drug screening, as well, now, to develope tumor that can be be used for precision research and ultimately clinical trials. It is a complex system, but with patients standing behind research through tumor donation consent – researchers can move forward faster and more efficiently with better knowledge through generated data from the tumor tissues. Ultimately, better understanding of the LMS tumor can lead to overcoming impediments to treatment options – expansion of treatments for the future is the goal for enhancing survivorship. Learn More here: https://youtu.be/M_ap5kc42i .
Jesse Boehm, Scientific Director, Cancer Dependency Map
Moony Tseng, Group Leader, Cell Line Factory
RCRF Cancer Cell Line project partnership with the NLMSF established to include leiomyosarcoma on APRIL 9, 2017:
The NLMSF encourages participation in this patient-driven project.
This offers a huge opportunity to move the needle forward for potential research initiatives across the globe. Researchers can access de-identified data for research initiatives/studies they wish to pursue. If you have questions about this program please contact Annie Achee at 303 783-0924 or 303 808-3437
If a patient is facing a biopsy or surgery to extract an LMS diagnosed tumor – tissue from the procedure(s) can be offered to the Rare Cancer Research Foundation (RCRF) through a simple consent form. The RCRF takes care of the rest of the coordination to make sure your de-identified tumor sample is sent to the Broad Institute of MIT / Harvard laboratories for cell processing and hopeful growth.
The Rare Cancer Research Foundation (RCRF) is dedicated to curing rare cancers through strategic investments and innovative collaborations that facilitate effective research and accelerate the deployment of promising therapies.